CANbridge Completes HK$2.38 New Share Subscription, Reshaping Shareholder Base

An update from CANbridge Pharmaceuticals Inc. ( (HK:1228) ) is now available.

CANbridge Pharmaceuticals has completed a share subscription under its general mandate, issuing 84,033,613 new shares at HK$2.38 each to a single subscriber. The transaction increases the company’s total issued share capital from 511,409,734 to 595,443,347 shares, marking a significant equity raise that broadens its capital base.

Following the issuance, the new subscriber’s stake rises from 2.51% to 16.26%, while existing major shareholder Baheal’s holding is diluted from 19.00% to 16.32%. The deal reshapes the company’s shareholder structure, potentially strengthening its financial position but diluting existing shareholders’ percentage interests, and may influence future governance dynamics and market perception.

The most recent analyst rating on (HK:1228) stock is a Buy with a HK$3.00 price target. To see the full list of analyst forecasts on CANbridge Pharmaceuticals Inc. stock, see the HK:1228 Stock Forecast page.

More about CANbridge Pharmaceuticals Inc.

CANbridge Pharmaceuticals Inc. is a Cayman Islands-incorporated biopharmaceutical company listed in Hong Kong under stock code 1228. The company focuses on developing and commercializing innovative therapies, with its shareholder base including founder and chairman Dr. James Qun Xue and strategic investor Baheal, alongside a broad group of public shareholders.

Average Trading Volume: 3,778,457

Technical Sentiment Signal: Buy

Current Market Cap: HK$1.27B

See more data about 1228 stock on TipRanks’ Stock Analysis page.